Externally Led Patient-Focused Drug Development (EL-PFDD) Meeting on Infertility and IVF


26 March
2026

10am to
3:30pm

Join Us
Virtually

Externally Led Patient-Focused Drug Development (EL-PFDD) Meeting on Infertility and IVF

26 March 2026,
10am to 3:30pm

Join Us Virtually

Fertility Preservation Toolkit

Thank you for your interest in our toolkits. Please read our Terms of Use carefully as we include information that applies to all our toolkits.

All toolkits are publicly available for individual use without licensing or royalty fees. Such use of toolkits is “single use,” meaning solely for the User’s research, clinical, educational, or other application. User’s email may be added to an email distribution list to receive scientific and updated information about the toolkit(s).

We encourage use of our toolkits. User agrees not to adapt, alter, amend, abridge, modify, condense, make derivative works, or translate toolkits without prior written permission from the Provider. User agrees not to sell or incorporate toolkits into materials that could be sold without prior written consent from the Provider. To inquire about permissions, please email info@a4fp.org.


Gwendolyn Quinn, PhD.

Gwendolyn Quinn, PhD.

Dr. Quinn has a Ph.D. in health psychology from Florida State University and post-graduate training in biomedical ethics. She is a Senior Member of Moffitt Cancer Center in the Health Outcomes and Behavior Program and Professor at the University Of South Florida College Of Medicine, Department of Oncologic Sciences. She is Director of the Moffitt Survey Methods Core.

Gwen’s research focuses on assessing the behavioral determinants of cancer patients’ decisions about provider recommendations. Current projects include training health care providers to discuss reproductive health and fertility preservation with AYA patients; adult and pediatric oncology health care providers barriers to discussion about sexuality and fertility; barriers to clinical trial participation; LGBTQ cancer health issues; ethical issues in genetic testing for hereditary cancer; the use of Preimplantation Genetic Diagnosis (PGD) for hereditary cancer populations; and training researchers to conduct research with high risk populations.